Ceritinib valuable treatment option in advanced ALK-positive lung cancer
- PDF / 167,276 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 65 Downloads / 189 Views
1
Ceritinib valuable treatment option in advanced ALK-positive lung cancer Ceritinib offers more health and QOL benefits than crizotinib in patients with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) at acceptable cost in Hong Kong. This is the main finding of a study that used a partitioned survival model to examine the cost effectiveness of first-line ceritinib 450mg orally once daily compared to crizotinib 250mg orally twice daily in the treatment of previously untreated patients with ALK+ advanced NSCLC in Hong Kong.* The model was populated with efficacy data from clinical trials. The analyses was performed from a healthcare service provider’s or government’s perspective. The model showed that first-line treatment with ceritinib 450mg was associated with more total life-years than crizotinib (4.51 vs 3.85) and more total QALYs (3.22 vs 2.68) at slightly higher total costs over a 20-year time horizon ($US157 581 vs $150 424; year 2018 values). Drug and drug administration costs during initial treatment were lower for ceritinib, but drug and drug administration costs during post-progression treatment and medical costs were higher for ceritinib. The incremental cost for ceritinib vs crizotinib was $13 343 per QALY gained. This value is substantially lower than the WHO threshold of three times GDP per capita ($US119 274 in Hong Kong). "With ceritinib’s recent introduction as a first-line targeted therapy, these results provide important insight for decision-makers considering treatments for ALK+ advanced NSCLC in Hong Kong," conclude the researchers. * The study was funded by Novartis Pharmaceuticals Corporation. Loong HH, et al. Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. Cost Effectiveness and Resource Allocation : 7 Nov 2020. Available from: URL: https://doi.org/10.1186/s12962-020-00244-6
1173-5503/20/0866-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803515671
PharmacoEconomics & Outcomes News 14 Nov 2020 No. 866
Data Loading...
